Takeo Arita

723 total citations · 1 hit paper
11 papers, 408 citations indexed

About

Takeo Arita is a scholar working on Molecular Biology, Organic Chemistry and Oncology. According to data from OpenAlex, Takeo Arita has authored 11 papers receiving a total of 408 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 5 papers in Organic Chemistry and 4 papers in Oncology. Recurrent topics in Takeo Arita's work include Melanoma and MAPK Pathways (7 papers), Synthesis and biological activity (5 papers) and Computational Drug Discovery Methods (4 papers). Takeo Arita is often cited by papers focused on Melanoma and MAPK Pathways (7 papers), Synthesis and biological activity (5 papers) and Computational Drug Discovery Methods (4 papers). Takeo Arita collaborates with scholars based in Japan, United States and Austria. Takeo Arita's co-authors include Sei Yoshida, Masanori Okaniwa, Tomoyasu Ishikawa, Akito Nakamura, Kenichi Suda, Michael Gmachl, Masato Chiba, T. Koga, Marco H. Hofmann and Tetsuya Mitsudomi and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Biochemical and Biophysical Research Communications.

In The Last Decade

Takeo Arita

11 papers receiving 404 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments

2021 167 citations T. Koga, Kenichi Suda et al. Journal of Thoracic Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Takeo Arita Japan	7	319	151	74	73	66	11	408
Sei Yoshida Japan	11	273 0.9×	112 0.7×	73 1.0×	24 0.3×	81 1.2×	22	372
Brian Zifcak United States	7	431 1.4×	136 0.9×	51 0.7×	45 0.6×	125 1.9×	10	570
Zenaida Go	2	262 0.8×	184 1.2×	71 1.0×	36 0.5×	41 0.6×	2	310
Henrik Moebitz Switzerland	5	325 1.0×	119 0.8×	58 0.8×	30 0.4×	105 1.6×	8	441
Edward J. Lewis United Kingdom	5	223 0.7×	150 1.0×	49 0.7×	77 1.1×	46 0.7×	5	360
Kazuhiro Ohara Japan	4	346 1.1×	138 0.9×	53 0.7×	45 0.6×	36 0.5×	6	407
Liv Johannessen United States	8	241 0.8×	152 1.0×	30 0.4×	57 0.8×	42 0.6×	19	374
Robert H. Sinnamon United States	6	510 1.6×	141 0.9×	66 0.9×	40 0.5×	35 0.5×	7	566
Elisabeth V. Schneider Germany	7	238 0.7×	172 1.1×	67 0.9×	76 1.0×	37 0.6×	8	409
Laurie S. Kane-Carson United States	6	326 1.0×	177 1.2×	102 1.4×	39 0.5×	135 2.0×	8	481

Countries citing papers authored by Takeo Arita

Since Specialization

Citations

This map shows the geographic impact of Takeo Arita's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Takeo Arita with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Takeo Arita more than expected).

Fields of papers citing papers by Takeo Arita

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Takeo Arita. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Takeo Arita. The network helps show where Takeo Arita may publish in the future.

Co-authorship network of co-authors of Takeo Arita

This figure shows the co-authorship network connecting the top 25 collaborators of Takeo Arita. A scholar is included among the top collaborators of Takeo Arita based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Takeo Arita. Takeo Arita is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Koyama, Shohei, Fumitaka Suto, Takeo Arita, et al.. (2024). The Tumor Immune Microenvironment and Therapeutic Efficacy of Trastuzumab Deruxtecan in Gastric Cancer. Cancer Research Communications. 5(1). 84–93. 1 indexed citations

Koga, T., Kenichi Suda, Toshio Fujino, et al.. (2021). KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments. Journal of Thoracic Oncology. 16(8). 1321–1332. 167 indexed citations breakdown →

Arita, Takeo, Megumi Morimoto, Yukiko Yamamoto, et al.. (2017). Prolyl-tRNA synthetase inhibition promotes cell death in SK-MEL-2 cells through GCN2-ATF4 pathway activation. Biochemical and Biophysical Research Communications. 488(4). 648–654. 16 indexed citations

Katoh, Taisuke, Takafumi Takai, Tetsuya Tsukamoto, et al.. (2016). Discovery and optimization of 1,7-disubstituted-2,2-dimethyl-2,3-dihydroquinazolin-4(1H)-ones as potent and selective PKCθ inhibitors. Bioorganic & Medicinal Chemistry. 24(11). 2466–2475. 19 indexed citations

Nakamura, Akito, Takeo Arita, Jill Donelan, et al.. (2013). Antitumor Activity of the Selective Pan-RAF Inhibitor TAK-632 in BRAF Inhibitor-Resistant Melanoma. Cancer Research. 73(23). 7043–7055. 92 indexed citations

Okaniwa, Masanori, Masaaki Hirose, Takeo Arita, et al.. (2013). Discovery of a Selective Kinase Inhibitor (TAK-632) Targeting Pan-RAF Inhibition: Design, Synthesis, and Biological Evaluation of C-7-Substituted 1,3-Benzothiazole Derivatives. Journal of Medicinal Chemistry. 56(16). 6478–6494. 90 indexed citations

Zhang, Julie, Jerome T. Mettetal, Kazuhide Nakamura, et al.. (2013). Use of combination treatment with the investigational RAF kinase inhibitor MLN2480 and the investigational MEK kinase inhibitor TAK-733 on the growth of BRAF-mutant and RAS-mutant preclinical models of melanoma and CRC.. Journal of Clinical Oncology. 31(15_suppl). e13529–e13529. 1 indexed citations

Zhang, Julie, Jerome T. Mettetal, Kazuhide Nakamura, et al.. (2013). Abstract C146: Combination treatment with the investigational RAF kinase inhibitor MLN2480 and the investigational MEK kinase inhibitor TAK-733 inhibits the growth of BRAF mutant and RAS mutant preclinical models of melanoma and CRC.. Molecular Cancer Therapeutics. 12(11_Supplement). C146–C146. 1 indexed citations

Okaniwa, Masanori, Masaaki Hirose, Takeo Arita, et al.. (2013). Abstract C255: Discovery of TAK-632: A selective kinase inhibitor of pan-RAF with potent antitumor activity against BRAF and NRAS mutant melanomas.. Molecular Cancer Therapeutics. 12(11_Supplement). C255–C255. 1 indexed citations

10.

Okaniwa, Masanori, Takashi Imada, Tomohiro Ohashi, et al.. (2012). Design and synthesis of novel DFG-out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors: 2. Synthesis and characterization of a novel imide-type prodrug for improving oral absorption. Bioorganic & Medicinal Chemistry. 20(15). 4680–4692. 8 indexed citations

11.

Hirose, Masaaki, Masanori Okaniwa, T. Miyazaki, et al.. (2012). Design and synthesis of novel DFG-out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors: 3. Evaluation of 5-amino-linked thiazolo[5,4-d]pyrimidine and thiazolo[5,4-b]pyridine derivatives. Bioorganic & Medicinal Chemistry. 20(18). 5600–5615. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact